ACS chemical neuroscience molecule spotlight on dimebon

Corey R. Hopkins

doi:10.1021/cn1000588

ACS chemical neuroscience molecule spotlight on dimebon

Corey R. Hopkins

Research output: Contribution to journal › Short survey › peer-review

10 Scopus citations

Abstract

Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.

Original language	English (US)
Pages (from-to)	587-588
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	1
Issue number	9
DOIs	https://doi.org/10.1021/cn1000588
State	Published - Sep 15 2010
Externally published	Yes

Keywords

AD
Alzheimer's Disease
Dimebon
Neurodegeneration
clinical trials

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn1000588

Cite this

@article{0284ec8a817e46c09d7738afbf18c38b,

title = "ACS chemical neuroscience molecule spotlight on dimebon",

abstract = "Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.",

keywords = "AD, Alzheimer's Disease, Dimebon, Neurodegeneration, clinical trials",

author = "Hopkins, {Corey R.}",

year = "2010",

month = sep,

day = "15",

doi = "10.1021/cn1000588",

language = "English (US)",

volume = "1",

pages = "587--588",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on dimebon

AU - Hopkins, Corey R.

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.

AB - Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer's disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.

KW - AD

KW - Alzheimer's Disease

KW - Dimebon

KW - Neurodegeneration

KW - clinical trials

UR - http://www.scopus.com/inward/record.url?scp=77956658482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956658482&partnerID=8YFLogxK

U2 - 10.1021/cn1000588

DO - 10.1021/cn1000588

M3 - Short survey

C2 - 22778847

AN - SCOPUS:77956658482

SN - 1948-7193

VL - 1

SP - 587

EP - 588

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 9

ER -

ACS chemical neuroscience molecule spotlight on dimebon

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this